Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation
therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin,
dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that
invasive laboratory testing and dose adjustment is not necessary. In circumstances of
excessive anticoagulation, such as overdoses, decreased kidney function, or instances of
significant bleeding, reversing dabigatran's effects may be necessary. Unlike warfarin, no …